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The main aims of this bibliographic review are to: 
• Introduce the hallmarks of cancer, the capabilities that enable normal cells to transform to cancerous cells 
• Briefly describe the history of the identification of tumor suppressor genes  (TSGs) 
• Review and synthesize the principal tumor suppressor pathways, their involvement in cancer pathogenesis and the consequences of their inactivation or loss of function  
• Introduce the genetic and epigenetic modifications associated with TSGs 
• Briefly compare the information available in human and veterinary medicine regarding TSGs 
Objectives 
 
• Suppressors of cell cycle proliferation  
• Recessive autosomic inheritance   
• The inheritance of a single mutant allele increases susceptibility to caner  
• Related to familial cancers or inherited predisposition to cancer 
• The same gene is frequently inactivated in sporadic cancers 
 
Tumor suppressor genes 
 
1. Sustaining proliferative signalling  
2. Insensitivity to anti-growth signals  
3. Evading apoptosis 
4. Replicative immortality  
5. Inducing angiogenesis  
6. Tissue invasion and metastasis 
Hallmarks of cancer  
 
 
 
 
 
 
 
 
 
RB 
 
• Mutations  
• Loss of heterozygosity  
• DNA Methylation  
• miRNAs  
Inactivation of TSG 
Genetic  
Epigenetic  
• First TSG described in inherited 
retinoblastoma  
• RB irreversibly blocks cell cycle progression 
(G1/S phase) 
• Mutated in many cancers: breast cancer, 
small cell lung cancer and bladder cancer 
p53: the guardian of the genome  
New diagnostic and 
therapeutic strategies  
 
•  The identification of RB and TP53 helped to establish the basis for further 
studies about TSG and their characteristics as cancer-associated genes 
•  TSGs are key regulators of cell cycle progression 
• The main properties of TSGs may be resumed as: having a recessive 
autosomic inheritance, act as suppressors of cell cycle progression and being 
related to familial and sporadic cancers or inherited predisposition to cancer 
• TP53 is the most frequently mutated TSG in cancer because of its involvement 
in many tumor suppressor mechanisms 
• TSGs are silenced by genetic and epigenetic modifications, which hold 
promise for developing new therapeutic and diagnostic strategies. 
• TSGs may be suitable targets for anticancer therapies that proved to be 
effective both in vitro and in vivo although further research is needed.   
• TSGs are highly conserved in mammals and pets are proper animal models for 
human cancer. 
Conclusions  
 
 
 
 
 
 
 
 
PTEN 
• Suppressor of cell proliferation  
• Negative regulator of the PI3K/AKT 
cascade 
• Mutated in numerous cancers: central 
nervous system, skin and prostate 
cancers.  
•  Germ line mutations are associated 
with Cowden’s disease  
 
 
•  TP53 is the most frequently mutated TSG in cancer (40 – 50%) 
•  Missense mutations (~74%) within the central binding domain 
•  Mutant p53 inhibits wild type p53 preventing genome protection  
•  Inhibition of mutant p53 as an effective therapy for malignant phenotypes? 
• Effective in vitro and in vivo  further studies required  
 
 
 
 
p53 mutations  
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•  TSGs and tumor suppressor pathways are highly conserved in mammals 
•  Alterations in RB, TP53 or PTEN are present in many animal and human cancers 
•  Pets are suitable animal models for human diseases such as cancer 
•  The lack of standards of care for pets provides an opportunity for 
experimental therapies that benefit both animal and human cancer patients 
Human and veterinary medicine  
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